Waltham, MA-based Syndax Pharmaceuticals named former AstraZeneca chief medical officer Briggs Morrison its new CEO, and Michael Metzger, onetime Regado Biosciences president and CEO, its new president. Morrison and and Metzger are replacing former leader Arlene Morris—whose name was conspicuously absent from the news release. FierceBiotech first reported news of Morrison’s departure from AstraZeneca last week. Read more here for the immuno-oncology focused strategy that Syndax—which flirted with an IPO last year under Morris—intends to pursue.
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
